Moderna TX, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$81.4M
Doctors Paid
40
Transactions
66,521
2021 Total
$81.4M
Payment Breakdown by Category
Research$80.0M (98.2%)
Consulting$1.3M (1.6%)
Royalty/License$27,880 (0.0%)
Food & Beverage$52.02 (0.0%)
Travel$40.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $80.0M | 66,445 | 98.2% |
| Consulting Fee | $1.3M | 65 | 1.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $76,250 | 4 | 0.1% |
| Royalty or License | $27,880 | 5 | 0.0% |
| Food and Beverage | $52.02 | 1 | 0.0% |
| Travel and Lodging | $40.00 | 1 | 0.0% |
Payments by Type
Research
$80.0M
66,445 transactions
General
$1.4M
76 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older | $63.7M | 3 | 64,397 |
| A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age | $7.3M | 0 | 95 |
| A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | $5.2M | 2 | 266 |
| A PHASE 2a, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, DOSE-CONFIRMATION STUDY TO EVALUATE THE SAFETY, REACTOGENICITY, AND IMMUNOGENICITY OF MRNA-1273 SARS-COV-2 VACCINE IN ADULTS AGED 18 YEARS AND OLDER | $1.1M | 0 | 19 |
| A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged | $924,324 | 3 | 53 |
| A Phase 1, Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18-55 Years | $279,848 | 0 | 1,302 |
| A prospective study of rheumatoid arthritis disease activity and immunogenicity following COVID-19 vaccination (RADAVA) | $266,093 | 0 | 2 |
| A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 When Administered to Healthy Adults | $260,022 | 0 | 25 |
| A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS CoV 2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls | $147,161 | 3 | 26 |
| A longitudinal, exploratory, natural history study to further characterize and describe the signs and symptoms of patients with organic acidemias. | $125,153 | 0 | 86 |
| A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors | $92,517 | 0 | 18 |
| Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, IL-23, and IL-36 for Intratumoral Injection alone and in Combination with Checkpoint Blockade | $89,264 | 0 | 10 |
| A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate the Safety, Tolerability, and Immunogenicity of Lyophilized Zika Vaccine mRNA-1893 in Adults Aged 18-65 Years and Living in Endemic and Non Endemic Flavivi | $78,869 | 3 | 29 |
| A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION STUDY OF mRNA-2416, A LIPID NANOPARTICLE ENCAPSULATED mRNA ENCODING HUMAN OX40L, FOR INTRATUMORAL INJECTION TO PATIENTS WITH ADVANCED MALIGNANCIES | $77,375 | 0 | 6 |
| A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Lyophilized Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults | $66,257 | 0 | 5 |
| A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | $58,628 | 2 | 22 |
| A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma. | $42,773 | 0 | 7 |
| Phase 1/2, randomized, observer-blind, dose-ranging study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1010 candidate seasonal influenza vaccine in healthy adults 18 years and older | $42,323 | 1 | 25 |
| A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants | $36,063 | 0 | 22 |
| Phase 1 Interventional | $34,859 | 0 | 11 |
| A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine When Administered to Adults, | $27,024 | 0 | 6 |
| A Phase 2, Non-Randomized, Observer-Blind, Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus mRNA-1647 Vaccine in Participants who completed the mRNA-1647-P202 Study | $21,750 | 0 | 4 |
| A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults | $12,980 | 0 | 2 |
| A Global, Phase 1/2, Open-Label, Dose Optimization Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of mRNA 3705 in Participants with Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency | $2,700 | 2 | 2 |
| Observational Pregnancy Outcomes Study (COVE Pregnancy Study) | $500.00 | 1 | 1 |
| A Global, Phase 1/2, Open-label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA 3927 in Participants with Propionic Acidemia | $450.00 | 1 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Pediatric Infectious Diseases | $346,285 | 7 | $49,469 |
| Pediatrics | $95,104 | 6 | $15,851 |
| Infectious Disease | $89,503 | 5 | $17,901 |
| Internal Medicine | $57,250 | 4 | $14,313 |
| Cardiovascular Disease | $45,150 | 4 | $11,288 |
| Hematology & Oncology | $40,000 | 2 | $20,000 |
| Diagnostic Radiology | $9,800 | 2 | $4,900 |
| Gastroenterology | $3,500 | 2 | $1,750 |
| Clinical Genetics (M.D.) | $2,300 | 3 | $766.67 |
| Critical Care Medicine | $1,600 | 1 | $1,600 |
| Family | $900.00 | 1 | $900.00 |
| Dermatology | $400.00 | 1 | $400.00 |
| Pulmonary Disease | $52.02 | 1 | $52.02 |
| Obstetrics & Gynecology | $40.00 | 1 | $40.00 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Dr. Karen Slobod, Md, MD | Pediatric Infectious Diseases | Memphis, TN | $325,980 | $0 |
| Dr. Michael Simon, M.d, M.D | Pediatrics | Nicholasville, KY | $88,254 | $0 |
| Judith Wolf, Md, MD | Infectious Disease | Philadelphia, PA | $52,500 | $0 |
| Dr. Elizabeth Nabel, M.d, M.D | Cardiovascular Disease | Boston, MA | $38,750 | $0 |
| Sandra Horning, M.d, M.D | Hematology & Oncology | Stanford, CA | $37,500 | $0 |
| Dr. Anthony Faugno, M.d, M.D | Internal Medicine | Boston, MA | $28,000 | $0 |
| Dr. Eric Rosenberg, Md, MD | Internal Medicine | Boston, MA | $25,250 | $0 |
| Dr. Richard Hamill, M.d, M.D | Infectious Disease | Houston, TX | $24,500 | $0 |
| Dr. Ralph Weissleder, Md Phd, MD PHD | Diagnostic Radiology | Boston, MA | $8,000 | $0 |
| Dr. Jaime Fergie, M.d, M.D | Pediatric Infectious Diseases | Corpus Christi, TX | $8,000 | $0 |
| Dr. Michael Diamond, Md, MD | Infectious Disease | Saint Louis, MO | $6,583 | $0 |
| David Bernstein, M.d, M.D | Pediatric Infectious Diseases | Cincinnati, OH | $4,655 | $0 |
| Marc Sabatine, Md, MD | Cardiovascular Disease | Boston, MA | $4,000 | $0 |
| Dr. Michael Polis, M.d, M.D | Infectious Disease | Bethesda, MD | $3,678 | $0 |
| James Conway, Md, MD | Pediatric Infectious Diseases | Madison, WI | $3,400 | $0 |
| Hanny Al-Samkari, Md, MD | Hematology & Oncology | Boston, MA | $2,500 | $0 |
| Robert Flaumenhaft, M.d, M.D | Internal Medicine | Boston, MA | $2,400 | $0 |
| Richard Sutton, Md, MD | Infectious Disease | West Haven, CT | $2,243 | $0 |
| Joseph St.geme, M.d, M.D | Pediatrics | Philadelphia, PA | $2,000 | $0 |
| Fredric Gordon, M.d, M.D | Gastroenterology | Boston, MA | $2,000 | $0 |
| Ruth Karron, M.d, M.D | Diagnostic Radiology | Baltimore, MD | $1,800 | $0 |
| Leslie Cooper, Md, MD | Cardiovascular Disease | Jacksonville, FL | $1,650 | $0 |
| Stuart Adler, Md, MD | Pediatrics | Richmond, VA | $1,600 | $0 |
| Dr. Justin Ortiz, M.d, M.D | Critical Care Medicine | Baltimore, MD | $1,600 | $0 |
| Mark Russo, Md, MD | Internal Medicine | Greensboro, NC | $1,600 | $0 |
Ad
Top Products
- Moderna Covid-19 Vaccine $78.3M
Payment Categories
- Food & Beverage $52.02
- Consulting $1.3M
- Travel & Lodging $40.00
- Research $80.0M
- Royalties $27,880
About Moderna TX, Inc.
Moderna TX, Inc. has made $81.4M in payments to 40 healthcare providers, recorded across 66,521 transactions in the CMS Open Payments database. In 2021, the company paid $81.4M. The top product by payment volume is Moderna Covid-19 Vaccine ($78.3M).
Payments were distributed across 14 medical specialties. The top specialty by payment amount is Pediatric Infectious Diseases ($346,285 to 7 doctors).
Payment categories include: Food & Beverage ($52.02), Consulting ($1.3M), Research ($80.0M), Travel & Lodging ($40.00), Royalties ($27,880).